April 10, 2021
Business News

BioAesthetics Surpasses Series A Goal Further Advancing the Nipple-Areolar Complex Graft to Clinical Use

RESEARCH TRIANGLE PARK, N.C.–()–BioAesthetics Corporation today announced that it has significantly surpassed its Series A funding goal of $2.5 million, further advancing its inaugural product — the nipple-areolar complex (NAC) graft, or NACgraftTM, for patients who are undergoing breast reconstruction following breast cancer and mastectomy — to clinical use.

BioAesthetics’ Series A was led by a personal commitment from its Director Sandra Coufal, MD, of Sibling Capital Ventures. Dr. Coufal explained, “To mark the 5-year anniversary of my own survival from breast cancer, I felt that support for the development of this product [NACgraft™] and company was a priority investment for me personally in order to…

Click here to view the original article.

Related Posts

You might also like ...

Article feature image
Why Amazon workers in Alabama voted against union – Fox Business
Article feature image
Brooklyn woman gets COVID 3 weeks after Johnson & Johnson vaccine – New York Post
EIG ondertekent infrastructuurovereenkomst van $ 12,4 miljard met Aramco